November 18, 2016 — InspireMD Inc. announced in mid-October the online publication of positive clinical data in a new ...
Mitralign Inc. announced the successful compassionate use treatment of a patient suffering from tricuspid regurgitation (TR) with their investigational Trialign System. The patient was suffering from TR due to a cardiac implantable electronic device lead.
Boston Scientific recently announced results from the first clinical trial evaluating the performance of the HeartLogic Heart Failure Diagnostic Service to predict impending heart failure (HF) decompensation. Data collected from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study were presented as a late-breaking clinical trial at the American Heart Association (AHA) Scientific Sessions 2016, Nov. 12-16 in New Orleans, and confirmed the HeartLogic alert provided a highly sensitive and timely predictor of a future HF event.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
DAIC Editor Dave Fornell takes a video tour of some of the most innovative new interventional cardiology technologies he ...
A discussion with Juan Granada, M.D., about transcatheter mitral valve advancements and device challenges at the ...
A discussion with guidewire expert Dimitri Karmpaliotis, M.D., Ph.D., FACC, about the basics of interventional guidewire ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
A discussion with Torsten Vahl, M.D., about advancements in transcatheter valve repair technology, including new devices ...
A discussion with Simon Dixon, M.D., MBChB, on the use of fractional flow reserve-computed tomography (FFR-CT) to ...
TeraRecon, together with full-color 3-D printing cloud provider WhiteClouds, announced new technological and workflow process to print highly detailed models directly from the TeraRecon software. The new 3D Print Packs make online, cloud-based 3-D reconstruction and printing simple, fast and affordable.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the ...
Depression has been known to be associated with poor cardiovascular outcomes. But if patients who are depressed attend cardiac rehabilitation after heart surgery, their risk of death is significantly reduced, according to a new study.
Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions, according to a new study from the Intermountain Medical Center Heart Institute.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Computational Signal Detection (CSD) Laboratories LLC announced the publication of data in support of the clinical utility of its eMurmur computer-aided auscultation (CAA) platform for early and ongoing heart-health screening of children.
Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the Claria MRI Quad Cardiac Resynchronization Therapy Defibrillator (CRT-D) SureScan device for patients with heart failure. The Claria MRI CRT-D is approved for scanning in both 1.5 and 3 Tesla (T) magnetic resonance imaging (MRI) machines, and features EffectivCRT, a new algorithm that automatically tailors the therapy to individual patients by adjusting pacing rates.
Many people who experience chest pain but don’t have a heart attack breathe a big sigh of relief when a stress test comes back negative for blockages in their blood vessels. But a new study by cardiac researchers at the Intermountain Medical Center Heart Institute in Salt Lake City found they may not be off the hook after all.